ORAMED PHARMACEUTICALS INC

NASDAQ: ORMP (Oramed Pharmaceuticals Inc.)

Last update: 23 hours ago

3.71

-0.32 (-7.94%)

Previous Close 4.03
Volume 161,315
Price / Sales 90.99
Price / Book 0.530
52 Weeks Range
2.25 (-39%) — 5.47 (47%)
TTM Dividend Yield 6.74%
Operating Margin (TTM) -225.00%
Diluted EPS (TTM) -0.710
Total Debt/Equity (MRQ) 0.22%
Current Ratio (MRQ) 23.94
Operating Cash Flow (TTM) -10.46 M
Levered Free Cash Flow (TTM) -1.51 M
Return on Assets (TTM) -5.10%
Return on Equity (TTM) -18.51%

AIStockmoo Score

0.5
Value 30% 0.0
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info
Return on Capital info NA
Timing 30% -0.5
From our AI technical analysis of the chart. info NA
Uptrend over the past year. Far below its 52-week high. info
Candle Patterns info NA
Trend for Your Holding Period info NA
Sentiment 20% 0.0
No recent price targets, so based on how targets have been revised. info
News Mood info NA
Smart Money 20% 3.2
Insider Activity info NA
Institutions net +18.26% of shares in their latest 13F filings: 56 holders increased, 23 decreased (quarter to 30 Sep 2026). info
Short interest +16.4% from 31 Aug to 30 Oct 2026, 11.3 days to cover (FINRA). info
Market and sector conditions are poor.
Market environment cautious. info
Sector lagging the market.
The pillars agree, so the score is strengthened.
Not in score
Price is near its 52-week average. Down over 5 years. info
Short-term momentum falling. info
Price is between support and resistance. Levels trending down. info
Final Score 0.46

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bullish
Biotechnology (Global) Mixed Bullish
Stock Oramed Pharmaceuticals Inc. Mixed Mixed

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
ORMP - 6.74% - 0.530
OPT 583 M - - 4.31
OCUP 51 M - - 0.870
CTMX - - - 1.55
ZYME - - - 7.29
PBYI - - - 2.73

Select this tab to load the latest available analysis.

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.

Sector Healthcare
Industry Biotechnology
Investment Style Small Core
% Held by Insiders 13.21%
% Held by Institutions 19.12%

Ownership

Name Date Shares Held
Sb Capital Management Inc 31 Dec 2025 1,900,000

No data within this time range.

No data within this time range.

Institutions

Institutional ownership: 46.16%

Positions Holders Shares
Increased 56 6,335,923
Decreased 23 704,680
New 23 2,573,118
Sold out 8 350,717

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

Short Interest

Settlement Shares Days to cover
30 Oct 2026 1,343,457 11.3
15 Oct 2026 1,451,095 10.4
30 Sep 2026 1,433,436 7.3
15 Sep 2026 1,307,745 7.4
31 Aug 2026 1,154,241 4.3
14 Aug 2026 1,025,767 5.9

FINRA short interest via Nasdaq, reported twice a month.

0 Positive 0 Negative 1 Neutral
Date Type Details
12 Nov 2026 Yahoo Finance Oramed: Q3 Earnings Snapshot
NEW YORK (AP) — NEW YORK (AP) — Oramed Pharmaceuticals Inc. (ORMP) on Thursday reported profit of $134…
08 Sep 2026 Yahoo Finance Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy
HUDSON, Mass. and YOKNEAM ILLIT, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced that an…
28 Aug 2026 Yahoo Finance ORMP: Investment Gains Contributed to Strong 2Q26 EPS, While Inclusion in Russell Indexes Arguably Boosts Awareness
By M. Marin NASDAQ: ORMP READ THE FULL ORMP RESEARCH REPORT Gains on investment portfolio + service agreement income contributed to 2Q26 EPS of $2.76 Oramed Pharmaceuticals (NASDAQ: ORMP) leverages its strong balance sheet, with $15.2 million of cash and equivalents and $50.6 million of cash and…
17 Aug 2026 Yahoo Finance Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee
WALTHAM, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension,” “Nano,” or the “Company”) today announced the appointment of Nadav Kidron to its Board of Directors (the “Board”). As part of the Board’s ongoing strategic review, led by Chairman Phillip…
TTM Dividend Yield 6.74%
Expected Next Dividend Payment Jan 2027
Ex Date Announcement Date Payment Date Details
16 Jan 2026 - 26 Jan 2026 0.25 Cash

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2026 0.250 1 6.74

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria